Simultaneous EGFR and BRAF Inhibition Is Proven Effective in BRAF V600-Mutated, Metastatic Colorectal Cancer
The presence of BRAF V600E mutations in metastatic colorectal cancer (mCRC) has long been known to be associated with an extremely poor prognosis with a median survival of about 12 to 15 months in clinical trials. In contrast to melanoma carrying the very same mutation, single-agent BRAF inhibitors, or combinations of BRAF and MEK inhibitors, […]
